Category: 93319-65-4

Downstream synthetic route of 93319-65-4

93319-65-4 Pyridazin-3-ylmethanamine 22639518, apyridazine compound, is more and more widely used in various fields.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.93319-65-4,Pyridazin-3-ylmethanamine,as a common compound, the synthetic route is as follows.

93319-65-4, General procedure: A solution of 1-isopropyl-6-methyl-4-oxo-5-(3-trifluoromethyl-phenyl)-1,4-dihydro-pyridine-3-carboxylic acid (preparation 3, 65 mg, 0.192 mmol), TBTU (75 mg, 0.232 mmol), N-methylmorpholine (42 muL, 0.383 mmol) in DMF (1 mL) is stirred for 15 min at room temperature. C-(5-Methyl-[1,3,4]oxadiazol-2-yl)-methylamine (24 mg, 0.211 mmol) is added and the reaction mixture is stirred for 18 h at room temperature. The reaction mixture is purified by preparative reversed-phase HPLC (Sunfire, gradient of acetonitrile in water, 0.1% TFA, 60 C.). The following examples are prepared as described for Example 3.1, substituting preparation 3 with preparation 4, substituting N-methylmorpholine with triethylamine and employing the appropriate amines, respectively.

93319-65-4 Pyridazin-3-ylmethanamine 22639518, apyridazine compound, is more and more widely used in various fields.

Reference£º
Patent; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; OOST, Thorsten; FIEGEN, Dennis; GNAMM, Christian; HANDSCHUH, Sandra; PETERS, Stefan; ROTH, Gerald Juergen; US2014/57920; (2014); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

 

New learning discoveries about 93319-65-4

93319-65-4 Pyridazin-3-ylmethanamine 22639518, apyridazine compound, is more and more widely used in various fields.

93319-65-4,93319-65-4, Pyridazin-3-ylmethanamine is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}- 1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 muetaetaomicronIota, intermediate 1 ) in DMF (1 .3 mL) was added 1 -(pyridazin-3-yl)methanamine (28.2 mg, 259 muetaetaomicronIota) and this mixture was stirred at 55 C over night. Additional 1 -(pyridazin-3-yl)methanamine (14.1 mg, 129 muetaetaomicronIota) was added and stirred over night at 60C. After cooling to room temperature ethyl acetate and water was added. After separation of the organic phase the aqueous phase was extracted two times with ethyl acetate. The combined organic phases were washed with brine, dried over sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified via a Biotage chromatography system (1 Og snap KP-Sil column, hexane / 0 – 100% ethyl acetate, then ethyl acetate / 0 – 100% methanol) to obtain 190 mg (84 % purity, 103 % yield) of the desired title compound. -NMR (400 MHz, DMSO-d6) delta [ppm]: -0.1 1 – -0.06 (m, 9H), 0.79 – 0.86 (m, 2H), 3.54 – 3.61 (m, 2H), 4.62 (d, 2H), 5.68 (s, 2H), 6.58 (d, 1 H), 7.23 (t, 1 H), 7.37 – 7.45 (m, 2H), 7.64 (dd, 1 H), 7.70 (dd, 1 H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.15 (dd, 1 H), 9.43 (s, 1 H).

93319-65-4 Pyridazin-3-ylmethanamine 22639518, apyridazine compound, is more and more widely used in various fields.

Reference£º
Patent; BAYER PHARMA AKTIENGESELLSCHAFT; DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG; BAYER AKTIENGESELLSCHAFT; BUCHMANN, Bernd; SCHMEES, Norbert; MOWAT, Jeffrey Stuart; LEDER, Gabriele; PANKNIN, Olaf; CARRETERO, Rafael; AIGUABELLA FONT, Nuria; BRIEM, Hans; FRIBERG, Anders Roland; HUSEMANN, Manfred; BOeMER, Ulf; STOeCKIGT, Detlef; NEUHAUS, Roland; BERNDT, Sandra; PETERSEN, Kirstin; OFFRINGA, Rienk; (494 pag.)WO2018/228920; (2018); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

 

Simple exploration of 93319-65-4

The synthetic route of 93319-65-4 has been constantly updated, and we look forward to future research findings.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.93319-65-4,Pyridazin-3-ylmethanamine,as a common compound, the synthetic route is as follows.

The title compound is prepared according to General Procedure 13 described in Example 52, using 3-{[8-(1-methyl-1 -/-indol-6-yl)quinoxalin-6- yl]amino}pyridine-4-carboxylic acid (Intermediate 42, 80 mg; 0.20 mmol; 1 eq.), pyridazin-3-yl-methylamine (28 mg; 0.25 mmol; 1.25 eq.), EDC-HCI (69 mg; 0.35 mmol; 1.80 eq.), HOBt hydrate (55 mg; 0.35 mmol; 1.80 eq.), triethylamine (0.13 ml0.98 mmol; 5 eq.) and dioxane (5 ml_). Conditions: room temperature for 24 h. Purification by FCC (0% to 10% MeOH gradient in DCM) yields 3-{[8-(1-methyl- H-indol-6-yl)quinoxalin-6-yl]amino}-//- [(pyridazin-3-yl)methyl]pyridine-4-carboxamide (40 mg; 0.08 mmol; 41 %; yellow powder; HPLC purity: 97%).

The synthetic route of 93319-65-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SELVITA S.A.; FABRITIUS, Charles-Henry Robert Yves; NOWAK, Mateusz Oktawian; WIKLIK, Katarzyna Anna; SABINIARZ, Aleksandra Barbara; BIE?, Marcin Dominik; BUDA, Anna Malgorzata; GUZIK, Pawel Szczepan; BIA?AS, Arkadiusz Kacper; PAWLIK, Henryk Edward; BOUTARD, Nicolas Felix Pierre; (439 pag.)WO2016/180537; (2016); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem